Monitoring and defining early response: Where to draw the line?

Best Practice and Research: Clinical Haematology

Volumn 29, Issue 3, 2016, Pages 284-294

  Branford, Susan ^a,b,c  

^a CENTRE FOR CANCER BIOLOGY   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

BCR ABL1; Molecular monitoring; Response kinetics; Treatment response

Indexed keywords

PROTEIN TYROSINE KINASE INHIBITOR; BCR ABL PROTEIN; BCR-ABL1 FUSION PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

CHRONIC MYELOID LEUKEMIA; DISEASE COURSE; DRUG MONITORING; EVENT FREE SURVIVAL; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PHYSIOLOGIC MONITORING; PROCEDURES;

FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MONITORING, PHYSIOLOGIC; PROTEIN KINASE INHIBITORS;

EID: 84995480744     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2016.10.006     Document Type: Review

References (59)

1. [1] Baccarani, M., Deininger, M.W., Rosti, G., et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood 2013:122 (2013), 872-884.
2. [2] NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. Version 1, 2016 http://www.nccn.org.
3. [3] Hughes, T.P., Hochhaus, A., Branford, S., et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 116 (2010), 3758-3765.
4. [4] Hanfstein, B., Muller, M.C., Hehlmann, R., et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 26 (2012), 2096-2102.
5. [5] Marin, D., Ibrahim, A.R., Lucas, C., et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 30 (2012), 232-238.
6. [6] Hughes, T., Deininger, M., Hochhaus, A., et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108 (2006), 28-37.
7. [7] Branford, S., Cross, N.C.P., Hochhaus, A., et al. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia 20 (2006), 1925-1930.
8. [8] Branford, S., Fletcher, L., Cross, N.C.P., et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 112 (2008), 3330-3338.
9. [9] Muller, M.C., Cross, N.C.P., Erben, P., et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 23 (2009), 1957-1963.
10. [10] Foroni, L., Wilson, G., Gerrard, G., et al. Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia. Br J Haematol 153 (2011), 179-190.
11. [11] Zhang, T., Grenier, S., Nwachukwu, B., et al. Inter-laboratory comparison of chronic myeloid leukemia minimal residual disease monitoring: summary and recommendations. J Mol Diagn 9 (2007), 421-430.
12. [12] Mahon, F.X., Faberes, C., Pueyo, S., et al. Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients treated by recombinant interferon-alpha. Blood 92 (1998), 4059-4065.
13. [13] O'Brien, S.G., Guilhot, F., Larson, R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348 (2003), 994-1004.
14. [14] Hughes, T.P., Kaeda, J., Branford, S., et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349 (2003), 1423-1432.
15. [15] Hughes, T.P., Branford, S., White, D.L., et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood 112 (2008), 3965-3973.
16. [16] Saglio, G., Kim, D.-W., Issaragrisil, S., et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. NEJM 362 (2010), 2251-2259.
17. [17] Kantarjian, H., Shah, N.P., Hochhaus, A., et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362 (2010), 2260-2270.
18. [18] Preudhomme, C., Guilhot, J., Nicolini, F.E., et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 363 (2010), 2511-2521.
19. [19] Hehlmann, R., Lauseker, M., Jung-Munkwitz, S., et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol 29 (2011), 1634-1642.
20. [20] Yeung, D.T., Osborn, M.P., White, D.L., et al. TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood 125 (2015), 915-923.
21. [21] Brummendorf, T.H., Cortes, J.E., de Souza, C.A., et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol 168 (2015), 69-81.
22. [22] Wang, L., Pearson, K., Pillitteri, L., et al. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia. Br J Haematol 118 (2002), 771-777.
23. [23] Merx, K., Muller, M.C., Kreil, S., et al. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia 16 (2002), 1579-1583.
24. [24] Wang, L., Pearson, K., Ferguson, J.E., et al. The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br J Haematol 120 (2003), 990-999.
25. [25] Branford, S., Rudzki, Z., Harper, A., et al. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia 17 (2003), 2401-2409.
26. [26] Jabbour, E., Kantarjian, H.M., Saglio, G., et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 123 (2014), 494-500.
27. [27] Marin, D., Hedgley, C., Clark, R.E., et al. Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib. Blood 120 (2012), 291-294.
28. [28] Branford, S., Kim, D.-W., Soverini, S., et al. Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib. J Clin Oncol 30 (2012), 4323-4329.
29. [29] Jain, P., Kantarjian, H., Nazha, A., et al. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood 121 (2013), 4867-4874.
30. [30] Hughes, T.P., Saglio, G., Kantarjian, H.M., et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 123 (2014), 1353-1360.
31. [31] Millot, F., Guilhot, J., Baruchel, A., et al. Impact of early molecular response in children with chronic myeloid leukemia treated in the French Glivec phase 4 study. Blood 124 (2014), 2408-2410.
32. [32] Boquimpani, C., Schaffel, R., Biasoli, I., et al. Molecular responses at 3 and 6 months after switching to a second-generation tyrosine kinase inhibitor are complementary and predictive of long-term outcomes in patients with chronic myeloid leukemia who fail imatinib. Leuk Lymphoma 56 (2015), 1787-1792.
33. [33] Branford, S., Yeung, D.T., Parker, W.T., et al. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood 124 (2014), 511-518.
34. [34] Kim, D., Hamad, N., Lee, H.G., et al. BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase. Am J Hematol 89 (2014), 626-632.
35. [35] Neelakantan, P., Gerrard, G., Lucas, C., et al. Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. Blood 121 (2013), 2739-2742.
36. [36] Stahlberg, A., Hakansson, J., Xian, X., et al. Properties of the reverse transcription reaction in mRNA quantification. Clin Chem 50 (2004), 509-515.
37. [37] Fleige, S., Pfaffl, M.W., RNA integrity and the effect on the real-time qRT-PCR performance. Mol Aspects Med 27 (2005), 126-139.
38. [38] Müller, M.C., Erben, P., Saglio, G., et al. Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. Leukemia 22 (2008), 96-102.
39. [39] Nazha, A., Kantarjian, H., Jain, P., et al. Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. Haematologica 98 (2013), 1686-1688.
40. [40] Branford, S., Roberts, N., Yeung, D.T., et al. Any BCR-ABL reduction below 10% at 6 months of therapy significantly improves outcome for CML patients with a poor response at 3 months. Blood, 122, 2013, 254.
41. [41] Hanfstein, B., Shlyakhto, V., Lauseker, M., et al. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia 28 (2014), 1988-1992.
42. [42] Iriyama, N., Fujisawa, S., Yoshida, C., et al. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: results of the D-first study of Kanto CML study group. Am J Hematol 90 (2015), 282-287.
43. [43] Huet, S., Cony-Makhoul, P., Heiblig, M., et al. Major molecular response achievement in CML patients can be predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS ratio at an earlier time point of follow-up than currently recommended. PLoS One, 9, 2014, e106250.
44. [44] Lin, F., van Rhee, F., Goldman, J.M., et al. Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. Blood 87 (1996), 4473-4478.
45. [45] Branford, S., Yeung, D.T., Prime, J.A., et al. BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management. Blood 119 (2012), 4264-4271.
46. [46] van der Velden, V.H., Hochhaus, A., Cazzaniga, G., et al. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 17 (2003), 1013-1034.
47. [47] Beillard, E., Pallisgaard, N., van der Velden, V.H., et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia 17 (2003), 2474-2486.
48. [48] Cross, N.C., White, H.E., Colomer, D., et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia 29 (2015), 999-1003.
49. [49] Branford, S., Hughes, T.P., Rudzki, Z., Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol 107 (1999), 587-599.
50. [50] Melo, J.V., Gordon, D.E., Cross, N.C., et al. The ABL-BCR fusion gene is expressed in chronic myeloid leukemia. Blood 81 (1993), 158-165.
51. [51] Melo, J.V., Hochhaus, A., Yan, X.H., et al. Lack of correlation between ABL-BCR expression and response to interferon-alpha in chronic myeloid leukaemia. Br J Haematol 92 (1996), 684-686.
52. [52] de la Fuente, J., Merx, K., Steer, E.J., et al. ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia. Blood 98 (2001), 2879-2880.
53. [53] Gabert, J., Beillard, E., van der Velden, V.H., et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe against cancer program. Leukemia 17 (2003), 2318-2357.
54. [54] Emig, M., Saussele, S., Wittor, H., et al. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 13 (1999), 1825-1832.
55. [55] Schoch, C., Schnittger, S., Bursch, S., et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia 16 (2002), 53-59.
56. [56] Quintás-Cardama, A., Choi, S., Kantarjian, H.M., et al. Relative ratio of BCR-ABL1 transcript clearance improves the prognostic value ff single PCR assessment at the 3 and 6 month time points in patients with chronic myeloid leukemia in chronic phase treated in the Dasision study. Blood, 122, 2013, 3993.
57. [57] Yoshida, C., Fletcher, L., Ohashi, K., et al. Harmonization of molecular monitoring of chronic myeloid leukemia therapy in Japan. Int J Clin Oncol 17 (2012), 584-589.
58. [58] Pritchard, J., Lustgarten, S., Hodgson, G., et al. Analysis of the relationship between dose and BCR-ABL halving time in CP-CML patients treated with ponatinib or imatinib. 2015, European Hematology Association EHA20: 99885.
59. [59] Cortes, J., De Souza, C., Lopez, J.L., et al. Switching to nilotinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with suboptimal cytogenetic response (CyR) on imatinib: first results of the LASOR Trial. Blood, 123, 2013, 95.